Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2894512 (Tapinarof) in adult plaque psoriasis
NCT03202004Phase 3Withdrawn
- Sponsor
- GSK
- Start
- Jan 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing GSK2894512 1% cream with Vehicle cream (2 arms). Primary endpoint: Proportion of subjects with PGA score of clear or almost clear (0 or 1) and a minimum 2-grade improvement in PGA score from Baseline at 12 weeks. Planned start Jan 2018; status: withdrawn.
02
Drugs
tapinarof
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03202004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202004.